Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
15.04
+0.11 (0.74%)
Apr 13, 2026, 2:06 PM EDT - Market open
Janux Therapeutics Revenue
In the year 2025, Janux Therapeutics had annual revenue of $10.00M, down -5.55%.
Revenue (ttm)
$10.00M
Revenue Growth
-5.55%
P/S Ratio
91.00
Revenue / Employee
$91,743
Employees
109
Market Cap
914.91M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.00M | -588.00K | -5.55% |
| Dec 31, 2024 | 10.59M | 2.51M | 30.99% |
| Dec 31, 2023 | 8.08M | -529.00K | -6.14% |
| Dec 31, 2022 | 8.61M | 4.98M | 136.79% |
| Dec 31, 2021 | 3.64M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.72B |
| Xencor | 125.58M |
| CytomX Therapeutics | 76.20M |
| uniQure | 16.10M |
| Evommune | 13.00M |
| Aktis Oncology | 6.50M |
| Compass Therapeutics | 850.00K |
JANX News
- 12 days ago - Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment - Business Wire
- 6 weeks ago - Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - Business Wire
- 7 weeks ago - Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011 - Business Wire
- 2 months ago - Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer - Business Wire
- 2 months ago - Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million - Benzinga
- 2 months ago - Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug - Reuters
- 2 months ago - Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors - Business Wire
- 3 months ago - Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study - Business Wire